JP2014517841A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014517841A5 JP2014517841A5 JP2014511893A JP2014511893A JP2014517841A5 JP 2014517841 A5 JP2014517841 A5 JP 2014517841A5 JP 2014511893 A JP2014511893 A JP 2014511893A JP 2014511893 A JP2014511893 A JP 2014511893A JP 2014517841 A5 JP2014517841 A5 JP 2014517841A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- skin
- disease
- composition
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 15
- 210000003491 skin Anatomy 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 239000004480 active ingredient Substances 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 150000004492 retinoid derivatives Chemical class 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 2
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 2
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 claims 2
- 229960005339 acitretin Drugs 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 208000009621 actinic keratosis Diseases 0.000 claims 2
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims 2
- 229960002916 adapalene Drugs 0.000 claims 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 2
- 229960001445 alitretinoin Drugs 0.000 claims 2
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 claims 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 2
- 230000002924 anti-infective effect Effects 0.000 claims 2
- 229960002938 bexarotene Drugs 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 210000004207 dermis Anatomy 0.000 claims 2
- 210000002615 epidermis Anatomy 0.000 claims 2
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 claims 2
- 229960002199 etretinate Drugs 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 229960005280 isotretinoin Drugs 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- -1 liquid paraffin Chemical compound 0.000 claims 2
- 206010033675 panniculitis Diseases 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 claims 2
- 229960003471 retinol Drugs 0.000 claims 2
- 235000020944 retinol Nutrition 0.000 claims 2
- 239000011607 retinol Substances 0.000 claims 2
- 210000004304 subcutaneous tissue Anatomy 0.000 claims 2
- 229960001967 tacrolimus Drugs 0.000 claims 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 2
- 229960000565 tazarotene Drugs 0.000 claims 2
- 229960001727 tretinoin Drugs 0.000 claims 2
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims 1
- 229940043375 1,5-pentanediol Drugs 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 229960004099 azithromycin Drugs 0.000 claims 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 229960002227 clindamycin Drugs 0.000 claims 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 229960003276 erythromycin Drugs 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 1
- 229960002751 imiquimod Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 229940057995 liquid paraffin Drugs 0.000 claims 1
- 239000004530 micro-emulsion Substances 0.000 claims 1
- 229960004023 minocycline Drugs 0.000 claims 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims 1
- 229960005330 pimecrolimus Drugs 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 239000006104 solid solution Substances 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 229950009819 zotarolimus Drugs 0.000 claims 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims 1
Claims (14)
- 皮膚または皮膚付属器に影響を及ぼす疾患または症状の防止または処置に用いるための局所薬学的組成物であり、有効量の活性成分、および次式：
ＲＦＲＨ
（式中、ＲＦは、４〜１２個の炭素原子を有する線状過フッ化炭化水素セグメントであり、そしてＲＨは、４〜８個の炭素原子を有する線状アルキル基である）
で表わされる半フッ化アルカンを含む組成物であって、皮膚または皮膚付属器に投与される組成物。 - 前記半フッ化アルカンが、Ｆ４Ｈ５、Ｆ４Ｈ６、Ｆ４Ｈ８、Ｆ６Ｈ６およびＦ６Ｈ８（ここで、Ｆは過フッ化炭化水素セグメントを意味し、Ｈは非フッ化セグメントを意味し、そして数字はそれぞれのセグメントの炭素原子の数である）から選択される請求項１に記載の組成物。
- 液体、半固体溶液、乳濁液またはマイクロエマルションの形態である請求項１または２のいずれかに記載の組成物。
- エタノール、アセトン、酢酸エチル、イソプロピルアルコール、グリセロール、プロピレングリコール、ペンチレングリコール、ポリエチレングリコール、液体パラフィン、トリグリセリド油、ヒドロフルオロカーボン、例えばＨＦＡ１３４ａおよび／またはＨＦＡ２２７、および液体モノまたはジグリセリドから選択される生理学的に許容可能な共溶媒を含む請求項１〜３のいずれかに記載の組成物。
- 前記皮膚または皮膚付属器に影響を及ぼす疾患または症状が、乾癬、皮膚炎、紅斑、湿疹、アレルギー、座瘡、光線性角化症、真菌感染症、細菌感染症、ウイルス感染症、疣または酒さから選択される疾患または症状である、請求項１〜４のいずれかに記載の組成物。
- 前記疾患または症状が、皮膚の生きている表皮、真皮および／または皮下組織に影響を及ぼすものである、請求項１〜５のいずれかに記載の組成物。
- 前記疾患が乾癬であり、前記活性成分が免疫抑制剤またはレチノイドから選択される請求項１〜６のいずれかに記載の組成物。
- 前記免疫抑制剤が、タクロリムス、シロリムス、エベロリムス、タクロリムス、ピメクロリムス、リダフォロリムス、テムシロリムス、ゾタロリムスおよびシクロスポリンＡから選択される請求項７に記載の組成物。
- 前記レチノイドが、レチノール、レチナール、トレチノイン、イソトレチノイン、アリトレチノイン、エトレチネート、アシトレチン、タザロテン、ベキサロテンおよびアダパレンから選択される請求項７に記載の組成物。
- 前記疾患が座瘡であり、前記活性成分がレチノイドまたは抗感染薬から選択される請求項１〜６のいずれかに記載の組成物。
- 前記レチノイドが、レチノール、レチナール、トレチノイン、イソトレチノイン、アリトレチノイン、エトレチネート、アシトレチン、タザロテン、ベキサロテンおよびアダパレンから選択される請求項１０に記載の組成物。
- 前記抗感染薬が、アジスロマイシン、エリスロマイシン、クリンダマイシンまたはミノサイクリンから選択される請求項１０に記載の組成物。
- 前記疾患または症状が皮膚の光線性角化症であり、そして前記活性成分がジクロフェナク、５−フルオロウラシルおよびイミキモドから選択される請求項１〜６のいずれかに記載の組成物。
- 皮膚の生きている表皮、真皮および／または皮下組織に活性成分を送達するための請求項１〜１３に記載の組成物の使用。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11167552.6 | 2011-05-25 | ||
| EP11167552 | 2011-05-25 | ||
| EP11167732.4 | 2011-05-26 | ||
| EP11167732 | 2011-05-26 | ||
| PCT/EP2012/059787 WO2012160179A2 (en) | 2011-05-25 | 2012-05-24 | Topical pharmaceutical composition based on semifluorinated alkanes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016215748A Division JP6306126B2 (ja) | 2011-05-25 | 2016-11-03 | 半フッ化アルカンを基礎にした局所薬学的組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014517841A JP2014517841A (ja) | 2014-07-24 |
| JP2014517841A5 true JP2014517841A5 (ja) | 2015-07-09 |
| JP6039145B2 JP6039145B2 (ja) | 2016-12-07 |
Family
ID=46168482
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014511893A Active JP6039145B2 (ja) | 2011-05-25 | 2012-05-24 | 半フッ化アルカンを基礎にした局所薬学的組成物 |
| JP2016215748A Active JP6306126B2 (ja) | 2011-05-25 | 2016-11-03 | 半フッ化アルカンを基礎にした局所薬学的組成物 |
| JP2018040265A Active JP6901421B2 (ja) | 2011-05-25 | 2018-03-07 | 半フッ化アルカンを基礎にした局所薬学的組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016215748A Active JP6306126B2 (ja) | 2011-05-25 | 2016-11-03 | 半フッ化アルカンを基礎にした局所薬学的組成物 |
| JP2018040265A Active JP6901421B2 (ja) | 2011-05-25 | 2018-03-07 | 半フッ化アルカンを基礎にした局所薬学的組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10130707B2 (ja) |
| EP (3) | EP3192501B1 (ja) |
| JP (3) | JP6039145B2 (ja) |
| KR (2) | KR101790388B1 (ja) |
| CN (4) | CN109260193A (ja) |
| AU (3) | AU2012260787B2 (ja) |
| CA (1) | CA2834855C (ja) |
| DK (2) | DK3192501T3 (ja) |
| ES (3) | ES2808051T3 (ja) |
| HK (1) | HK1247116A1 (ja) |
| PL (2) | PL2714010T3 (ja) |
| PT (2) | PT3192501T (ja) |
| WO (1) | WO2012160179A2 (ja) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8911494B2 (en) | 2009-05-04 | 2014-12-16 | Valtech Cardio, Ltd. | Deployment techniques for annuloplasty ring |
| WO2011154942A2 (en) | 2010-06-07 | 2011-12-15 | Valtech Cardio, Ltd. | Apparatus and method for guide-wire based advancement of a rotation assembly |
| US8734467B2 (en) | 2009-12-02 | 2014-05-27 | Valtech Cardio, Ltd. | Delivery tool for implantation of spool assembly coupled to a helical anchor |
| BR112012023421B1 (pt) | 2010-03-17 | 2021-09-14 | Novaliq Gmbh | Composição farmacêutica para tratamento de aumento de pressão intraocular |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| PL2714010T3 (pl) | 2011-05-25 | 2017-08-31 | Novaliq Gmbh | Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach |
| EP2714008B1 (en) | 2011-05-25 | 2016-12-14 | Novaliq GmbH | Pharmaceutical composition for administration to nails |
| AU2013211645B2 (en) | 2012-01-23 | 2017-06-15 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
| CA2997744C (en) | 2012-09-12 | 2019-12-31 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
| CA3142049C (en) * | 2012-09-12 | 2023-08-29 | Novaliq Gmbh | Semifluorinated alkane compositions |
| AU2014209141B2 (en) | 2013-01-24 | 2018-05-10 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mTOR inhibitors |
| CA2918419C (en) | 2013-07-23 | 2022-05-03 | Novaliq Gmbh | Stabilized antibody compositions |
| US9522189B2 (en) * | 2013-12-20 | 2016-12-20 | Johnson & Johnson Consumer Inc. | Topical gel compositions including poly(monostearoyl glycerol-co-succinate) polymer and methods for enhancing the topical application of a benefit agent |
| EP2944324A1 (de) * | 2014-05-13 | 2015-11-18 | LTS LOHMANN Therapie-Systeme AG | Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen |
| WO2017055454A1 (en) | 2015-09-30 | 2017-04-06 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| DK3356313T3 (da) | 2015-09-30 | 2020-07-20 | Novaliq Gmbh | 2-perfluorhexyloktan til oftalmisk indgivelse |
| CN105663027B (zh) * | 2016-04-01 | 2018-12-18 | 中国人民解放军广州军区武汉总医院 | 西罗莫司外用制剂、其制备方法及用途 |
| JP2019520357A (ja) | 2016-06-23 | 2019-07-18 | ノバリック ゲーエムベーハー | 局所投与方法 |
| WO2018054932A1 (en) | 2016-09-22 | 2018-03-29 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| CN109906085B (zh) | 2016-09-23 | 2024-03-08 | 诺瓦利克有限责任公司 | 含有环孢素的眼用组合物 |
| US10751295B2 (en) * | 2016-11-09 | 2020-08-25 | Specialty Drug and Device, LLC | Compositions and methods for the removal of ear wax |
| CN110248657A (zh) | 2016-12-22 | 2019-09-17 | 诺瓦利克有限责任公司 | 用于治疗眼内炎性眼病的包含他克莫司的组合物 |
| JP7108631B2 (ja) | 2017-01-06 | 2022-07-28 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物およびその使用方法 |
| PL3612228T3 (pl) * | 2017-04-21 | 2024-04-08 | Dermaliq Therapeutics, Inc. | Kompozycje jodu |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| WO2018215638A1 (en) | 2017-05-26 | 2018-11-29 | Novaliq Gmbh | Pharmaceutical compositions comprising azithromycin |
| SG11202002640YA (en) | 2017-09-27 | 2020-04-29 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
| US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
| CA3091308A1 (en) | 2018-03-02 | 2019-09-06 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| WO2019206956A1 (en) | 2018-04-27 | 2019-10-31 | Novaliq Gmbh | Ophthalmic compositions comprising tafluprost for the treatment of glaucoma |
| JP2021530463A (ja) | 2018-07-02 | 2021-11-11 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物および使用方法 |
| AU2019345929B2 (en) * | 2018-09-27 | 2022-02-03 | Dermaliq Therapeutics, Inc. | Topical sunscreen formulation |
| CA3112504A1 (en) | 2018-09-27 | 2020-04-02 | Novaliq Gmbh | Lipid barrier repair |
| MY206642A (en) | 2018-10-12 | 2024-12-30 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| US12397039B2 (en) | 2019-02-13 | 2025-08-26 | Novaliq Gmbh | Compositions and methods for the treatment of ocular neovascularization |
| AU2020340561A1 (en) | 2019-09-06 | 2022-03-31 | Novaliq Gmbh | Ophthalmic composition for the treatment of uveitis |
| EP3861857A1 (en) * | 2020-02-07 | 2021-08-11 | Novaliq GmbH | Antiparasitic compositions |
| CN117982412B (zh) * | 2024-02-04 | 2024-09-17 | 济川(上海)医学科技有限公司 | 一种醋克利定眼用组合物及其药物制剂和用途 |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10022A (en) | 1853-09-13 | Lard-lamp | ||
| US2616927A (en) | 1950-05-12 | 1952-11-04 | Minnesota Mining & Mfg | Fluorocarbon tertiary amines |
| JPS5721312A (en) | 1980-07-12 | 1982-02-04 | Green Cross Corp:The | Breathable ointment |
| US4452818A (en) | 1982-03-19 | 1984-06-05 | Haidt Sterling J | Extraocular method of treating the eye with liquid perfluorocarbons |
| US5077036A (en) | 1986-01-14 | 1991-12-31 | Alliance Pharmaceutical Corp. | Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid |
| JPH0764702B2 (ja) | 1986-04-23 | 1995-07-12 | 鐘紡株式会社 | 多相乳化型化粧料 |
| JPS6452722A (en) | 1987-05-01 | 1989-02-28 | Anjierini Pharmaceut Inc | Ophthalmic composition |
| JP3046346B2 (ja) | 1990-03-12 | 2000-05-29 | 昭和電工株式会社 | 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤 |
| US5518731A (en) | 1990-09-27 | 1996-05-21 | Allergan, Inc. | Nonaqueous fluorinated drug delivery vehicle suspensions |
| US6458376B1 (en) | 1990-09-27 | 2002-10-01 | Allergan, Inc. | Nonaqueous fluorinated drug delivery suspensions |
| US5152997A (en) | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
| US5326566A (en) | 1991-05-17 | 1994-07-05 | Bristol-Myers Squibb Company | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
| FR2679150A1 (fr) | 1991-07-17 | 1993-01-22 | Atta | Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations. |
| US5336175A (en) | 1992-10-29 | 1994-08-09 | Mames Robert N | Method for the treatment of retinal detachments |
| DE4405627A1 (de) * | 1994-02-22 | 1995-08-24 | Hoechst Ag | Fluorkohlenwasserstoffe enthaltende Ölemulsionen |
| FR2720943B1 (fr) | 1994-06-09 | 1996-08-23 | Applic Transferts Technolo | Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples. |
| US6294563B1 (en) | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
| US5696164A (en) | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
| US5667809A (en) | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
| US5874481A (en) * | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
| DE19536504C2 (de) | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| US5874469A (en) | 1996-01-05 | 1999-02-23 | Alcon Laboratories, Inc. | Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs |
| RU2111738C1 (ru) | 1996-06-24 | 1998-05-27 | Акционерное общество "НИЗАР" | Средство для усиления солнцезащитной активности фотозащитных агентов |
| FR2752161B1 (fr) | 1996-08-07 | 1998-09-25 | Atta | Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles |
| US5863560A (en) | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
| IN184589B (ja) | 1996-10-16 | 2000-09-09 | Alza Corp | |
| DE19709704C2 (de) | 1997-03-10 | 1999-11-04 | Michael Georgieff | Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie |
| US5980936A (en) | 1997-08-07 | 1999-11-09 | Alliance Pharmaceutical Corp. | Multiple emulsions comprising a hydrophobic continuous phase |
| US5851544A (en) | 1997-12-18 | 1998-12-22 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Cosmetic skin or hair care compositions containing fluorocarbons infused with carbon dioxide |
| US5981607A (en) | 1998-01-20 | 1999-11-09 | Allergan | Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers |
| US6224887B1 (en) | 1998-02-09 | 2001-05-01 | Macrochem Corporation | Antifungal nail lacquer and method using same |
| DE19861012A1 (de) | 1998-03-18 | 1999-09-30 | Pharm Pur Gmbh | Behandlungsmittel für die Ophthalmologie |
| ATE252889T1 (de) | 1998-08-19 | 2003-11-15 | Skyepharma Canada Inc | Injizierbare wässerige propofoldispersionen |
| US6140374A (en) | 1998-10-23 | 2000-10-31 | Abbott Laboratories | Propofol composition |
| US6159977A (en) | 1998-11-16 | 2000-12-12 | Astan, Inc. | Therapeutic anti-fungal nail preparation |
| US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
| WO2000045790A2 (en) | 1999-02-08 | 2000-08-10 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
| WO2000054588A1 (en) | 1999-03-15 | 2000-09-21 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
| US6177477B1 (en) | 1999-03-24 | 2001-01-23 | American Home Products Corporation | Propofol formulation containing TRIS |
| US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| DE19926890C1 (de) | 1999-06-12 | 2000-07-27 | Pharm Pur Gmbh | Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie |
| DE19938668B4 (de) | 1999-08-14 | 2006-01-26 | Bausch & Lomb Inc. | Tränenersatzmittel |
| US6528086B2 (en) * | 1999-09-28 | 2003-03-04 | Zars, Inc. | Methods and apparatus for drug delivery involving phase changing formulations |
| JP2001158734A (ja) | 1999-12-02 | 2001-06-12 | Lion Corp | 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法 |
| US20030018044A1 (en) | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
| DE10024413A1 (de) | 2000-05-19 | 2001-12-06 | Mika Pharma Gmbh | Pharmazeutische und/oder kosmetische Zubereitung |
| DE10042412B4 (de) | 2000-08-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung |
| US6399087B1 (en) | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
| US20030027833A1 (en) | 2001-05-07 | 2003-02-06 | Cleary Gary W. | Compositions and delivery systems for administration of a local anesthetic agent |
| PT1423102E (pt) | 2001-09-04 | 2008-02-25 | Trommsdorff Arzneimittel | Emplastro para o tratamento de disfunções e perturbações o crescimento da unha |
| WO2003061554A2 (en) | 2002-01-26 | 2003-07-31 | Micro Science Tech Co., Ltd | Composition containing moutan root bark extract as active ingredient |
| MXPA06002163A (es) | 2003-08-25 | 2006-05-22 | Foamix Ltd | Espuma farmaceutica de penetracion. |
| US20050079210A1 (en) | 2003-10-09 | 2005-04-14 | Gupta Shyam K. | Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients |
| PL1670433T3 (pl) | 2003-10-10 | 2013-03-29 | Ferring Bv | Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze |
| US20050175541A1 (en) | 2003-11-19 | 2005-08-11 | Lanza Gregory M. | Enhanced drug delivery |
| GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| CA2563544A1 (en) | 2004-04-19 | 2005-10-27 | Centre National De La Recherche Scientifique (C.N.R.S.) | Lung surfactant supplements |
| JP2008501806A (ja) | 2004-06-08 | 2008-01-24 | オキュラリス ファーマ， インコーポレイテッド | 疎水性眼用組成物および使用方法 |
| KR20070040381A (ko) | 2004-07-01 | 2007-04-16 | 셰펜스 아이 리써치 | 눈의 장애 및 상태를 치료하는 조성물 및 방법 |
| US20060078580A1 (en) | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
| US7740875B2 (en) | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
| EP1688161A1 (en) * | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
| GB0511499D0 (en) * | 2005-06-06 | 2005-07-13 | Medpharm Ltd | Topical ungual formulations |
| AU2006310113A1 (en) | 2005-08-05 | 2007-05-10 | Bharat Serums & Vaccines Ltd. | Intravenous propofol emulsion compositions having preservative efficacy |
| FR2892023B1 (fr) | 2005-10-14 | 2009-09-25 | Galderma Sa | Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale |
| DE102005050431A1 (de) | 2005-10-21 | 2007-04-26 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe |
| DE102005055811A1 (de) * | 2005-11-23 | 2007-05-31 | Novaliq Gmbh | Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen |
| TWI376239B (en) | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
| MX2009000885A (es) | 2006-07-25 | 2009-02-05 | Osmotica Corp | Soluciones oftalmicas. |
| US20080089923A1 (en) | 2006-09-29 | 2008-04-17 | Burkstrand Michael J | Biodegradable ocular implants and methods for treating ocular conditions |
| DE102007055046A1 (de) | 2007-11-19 | 2009-05-28 | Fluoron Gmbh | Infusionslösung |
| US20090136430A1 (en) * | 2007-11-27 | 2009-05-28 | Dugger Harry A | Antihistamine/Corticosteroid preparations for the treatment of atopic dermatitis |
| PL2110126T3 (pl) | 2008-04-18 | 2012-04-30 | Novaliq Gmbh | Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej |
| US20100189765A1 (en) | 2008-11-26 | 2010-07-29 | Erickson Signe R | Implantable ocular drug delivery device and methods |
| JP4642905B2 (ja) | 2009-01-22 | 2011-03-02 | 株式会社資生堂 | 乳化化粧料 |
| US8501800B2 (en) | 2009-03-05 | 2013-08-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
| IT1393419B1 (it) | 2009-03-19 | 2012-04-20 | Medivis S R L | Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6. |
| WO2010146536A1 (en) | 2009-06-18 | 2010-12-23 | Koninklijke Philips Electronics N.V. | Suspension of particles with drug |
| JP5736635B2 (ja) | 2009-06-25 | 2015-06-17 | ライオン株式会社 | ドライアイ治療剤 |
| US9012503B2 (en) | 2009-06-25 | 2015-04-21 | Lion Corporation | Ophthalmic composition |
| RU2532027C2 (ru) * | 2009-07-24 | 2014-10-27 | Мика Фарма Гезельшафт Фюр Ди Энтвиклюнг Унд Фермарктунг Фармацойтишер Продукте Мбх | Жидкие композиции, способные к пенообразованию и включающие активные средства, и способы их получения и разработки |
| EP2332525A1 (en) | 2009-11-23 | 2011-06-15 | Novaliq GmbH | Pharmaceutical composition comprising propofol |
| EP2335735A1 (en) | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
| US20110223208A1 (en) | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| BR112012023421B1 (pt) | 2010-03-17 | 2021-09-14 | Novaliq Gmbh | Composição farmacêutica para tratamento de aumento de pressão intraocular |
| DE102010022567A1 (de) | 2010-06-02 | 2011-12-08 | Fluoron Gmbh | Zubereitung |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| MX353154B (es) | 2011-01-04 | 2017-12-20 | Novaliq Gmbh | Emulsiones de aceite/agua que comprenden alcanos semifluorados. |
| US20120219640A1 (en) | 2011-02-25 | 2012-08-30 | Wright Kenneth W | Anti-infective solution for athlete's foot |
| EP2714008B1 (en) | 2011-05-25 | 2016-12-14 | Novaliq GmbH | Pharmaceutical composition for administration to nails |
| PL2714010T3 (pl) | 2011-05-25 | 2017-08-31 | Novaliq Gmbh | Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach |
| US8758826B2 (en) | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
| AU2013211645B2 (en) | 2012-01-23 | 2017-06-15 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
| CA3142049C (en) | 2012-09-12 | 2023-08-29 | Novaliq Gmbh | Semifluorinated alkane compositions |
| CA2997744C (en) | 2012-09-12 | 2019-12-31 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
| EP2783703A1 (en) | 2013-03-25 | 2014-10-01 | B. Braun Melsungen AG | Semifluorocarbon compound containing contrast agent |
| CA2918419C (en) | 2013-07-23 | 2022-05-03 | Novaliq Gmbh | Stabilized antibody compositions |
| EP2944324A1 (de) | 2014-05-13 | 2015-11-18 | LTS LOHMANN Therapie-Systeme AG | Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen |
| WO2017055454A1 (en) | 2015-09-30 | 2017-04-06 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| DK3356313T3 (da) | 2015-09-30 | 2020-07-20 | Novaliq Gmbh | 2-perfluorhexyloktan til oftalmisk indgivelse |
| CN106176937A (zh) | 2016-08-24 | 2016-12-07 | 刘艺鹏 | 湿疹、痤疮软膏 |
| PL3612228T3 (pl) | 2017-04-21 | 2024-04-08 | Dermaliq Therapeutics, Inc. | Kompozycje jodu |
| CA3112504A1 (en) | 2018-09-27 | 2020-04-02 | Novaliq Gmbh | Lipid barrier repair |
| AU2019345929B2 (en) | 2018-09-27 | 2022-02-03 | Dermaliq Therapeutics, Inc. | Topical sunscreen formulation |
| US20220362382A1 (en) | 2019-08-09 | 2022-11-17 | Dermaliq Therapeutics, Inc | Topical composition comprising a prostaglandin analogue |
| EP3861857A1 (en) | 2020-02-07 | 2021-08-11 | Novaliq GmbH | Antiparasitic compositions |
-
2012
- 2012-05-24 PL PL12723683T patent/PL2714010T3/pl unknown
- 2012-05-24 CA CA2834855A patent/CA2834855C/en active Active
- 2012-05-24 ES ES17154837T patent/ES2808051T3/es active Active
- 2012-05-24 EP EP17154837.3A patent/EP3192501B1/en active Active
- 2012-05-24 PL PL17154837T patent/PL3192501T3/pl unknown
- 2012-05-24 ES ES12723683.4T patent/ES2623233T3/es active Active
- 2012-05-24 EP EP12723683.4A patent/EP2714010B1/en active Active
- 2012-05-24 JP JP2014511893A patent/JP6039145B2/ja active Active
- 2012-05-24 KR KR1020137033325A patent/KR101790388B1/ko active Active
- 2012-05-24 DK DK17154837.3T patent/DK3192501T3/da active
- 2012-05-24 WO PCT/EP2012/059787 patent/WO2012160179A2/en not_active Ceased
- 2012-05-24 PT PT171548373T patent/PT3192501T/pt unknown
- 2012-05-24 PT PT127236834T patent/PT2714010T/pt unknown
- 2012-05-24 ES ES17201124T patent/ES2962524T3/es active Active
- 2012-05-24 EP EP17201124.9A patent/EP3311802B1/en active Active
- 2012-05-24 CN CN201810782938.1A patent/CN109260193A/zh active Pending
- 2012-05-24 CN CN201710375364.1A patent/CN107397718A/zh active Pending
- 2012-05-24 CN CN201810165933.4A patent/CN108283623A/zh active Pending
- 2012-05-24 KR KR1020177030042A patent/KR20170122282A/ko not_active Ceased
- 2012-05-24 AU AU2012260787A patent/AU2012260787B2/en active Active
- 2012-05-24 CN CN201280025366.3A patent/CN103596554A/zh active Pending
- 2012-05-24 DK DK12723683.4T patent/DK2714010T3/en active
- 2012-05-24 US US14/122,044 patent/US10130707B2/en active Active
-
2016
- 2016-11-03 JP JP2016215748A patent/JP6306126B2/ja active Active
-
2017
- 2017-01-31 AU AU2017200622A patent/AU2017200622B2/en active Active
- 2017-09-29 US US15/721,259 patent/US10813999B2/en active Active
-
2018
- 2018-03-07 JP JP2018040265A patent/JP6901421B2/ja active Active
- 2018-05-25 HK HK18106802.5A patent/HK1247116A1/zh unknown
- 2018-07-20 AU AU2018206812A patent/AU2018206812B2/en active Active
-
2020
- 2020-10-16 US US17/072,923 patent/US11844836B2/en active Active
-
2022
- 2022-04-04 US US17/713,082 patent/US20220218828A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014517841A5 (ja) | ||
| JP2014515366A5 (ja) | ||
| ES2623233T3 (es) | Composición farmacéutica tópica a base de alcanos semifluorados | |
| JP2013507337A5 (ja) | ||
| CL2011002053A1 (es) | Composicion farmaceutica de espuma en aerosol en emulsion de aceite en agua que comprende un agente farmaceuticamente activo, agua, aceite, disolvente organico, componente tensoactivo, y propulsor; procedimiento de preparacion; uso para tratar enfermedades, o afecciones de la piel. | |
| RU2015104019A (ru) | Композиция для местного применения, содержащая пленкообразующий полимер, для доставки активного ингредиента на кожу | |
| JP2013515742A5 (ja) | ||
| JP2012131827A5 (ja) | ||
| HRP20230559T1 (hr) | Oftalmička formulacija polioksil lipida ili polioksil masne kiseline i tretman očnih stanja | |
| JP6563922B2 (ja) | ホスファチジルコリンを含む噴霧可能な局部用キャリアー及び組成物 | |
| JP2015521996A5 (ja) | ||
| JP2015531344A5 (ja) | ||
| JP2016538271A5 (ja) | ||
| US20150094370A1 (en) | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same | |
| JP2016508158A5 (ja) | ||
| JP2017226664A (ja) | Ｄｇｌａ、１５−ｏｈｅｐａおよび／または１５−ｈｅｔｒｅを含む医薬組成物、ならびにその使用方法 | |
| JP2015514782A5 (ja) | ||
| JP2017503798A5 (ja) | ||
| JP2018522875A5 (ja) | ||
| WO2014039964A3 (en) | Compounds and methods for modulating vascular injury | |
| RU2015103469A (ru) | Ретиноиды и их применение | |
| RU2013157087A (ru) | Целевая доставка ретиноидных соединений к сальным железам | |
| US20130267486A1 (en) | Polymeric topical compositions | |
| JP2011006380A5 (ja) | ||
| JP2016538288A5 (ja) |